SPAF Trial

Summary: Evaluated warfarin or aspirin versus placebo in patients with atrial fibrillation for thromboembolism prophylaxis. Aspirin versus placebo decreased primary events (stroke and embolization) by 42%. Combined primary events and death reduced by 32%. Warfarin versus placebo decreased primary events by 67% and combined primary events and death by 58%. Direct comparison of aspirin versus warfarin not available, but was investigated in SPAF-II trial.

Original Publication:

Circulation. 1991 Aug;84(2):527-39.

Eponym: Stroke Prevention in Atrial Fibrillation Study